JP2019523305A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523305A5
JP2019523305A5 JP2019526375A JP2019526375A JP2019523305A5 JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5 JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5
Authority
JP
Japan
Prior art keywords
particle size
tolucapon
transthyretin
malvern
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019526375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523305A (ja
JP7047236B2 (ja
Filing date
Publication date
Priority claimed from EP16382372.7A external-priority patent/EP3275433A1/en
Application filed filed Critical
Publication of JP2019523305A publication Critical patent/JP2019523305A/ja
Publication of JP2019523305A5 publication Critical patent/JP2019523305A5/ja
Application granted granted Critical
Publication of JP7047236B2 publication Critical patent/JP7047236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019526375A 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤 Active JP7047236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (3)

Publication Number Publication Date
JP2019523305A JP2019523305A (ja) 2019-08-22
JP2019523305A5 true JP2019523305A5 (OSRAM) 2020-08-13
JP7047236B2 JP7047236B2 (ja) 2022-04-05

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526375A Active JP7047236B2 (ja) 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤

Country Status (12)

Country Link
US (2) US11883538B2 (OSRAM)
EP (2) EP3275433A1 (OSRAM)
JP (1) JP7047236B2 (OSRAM)
KR (1) KR102484678B1 (OSRAM)
CN (1) CN109789100A (OSRAM)
AU (1) AU2017303333B2 (OSRAM)
DK (1) DK3490535T3 (OSRAM)
ES (1) ES2891355T3 (OSRAM)
MX (1) MX391116B (OSRAM)
PT (1) PT3490535T (OSRAM)
RU (1) RU2750670C2 (OSRAM)
WO (1) WO2018019997A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
EP0901372B1 (en) 1996-05-20 2005-07-20 G.D. Searle LLC. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
ES2272066T3 (es) 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1585500B8 (en) * 2002-12-20 2017-07-26 Auritec Pharmaceuticals Coated particles for sustained-release pharmaceutical administration
US20080187590A1 (en) * 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
JP5902705B2 (ja) * 2010-11-15 2016-04-13 ニューロダーム リミテッドNeuroderm Ltd L−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−o−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
TR201802550T4 (tr) 2011-03-14 2018-03-21 Boehringer Ingelheim Int Lökotrien üretiminin benzodioksan inhibitörleri.
PL2770988T3 (pl) * 2011-10-24 2017-01-31 Som Innovation Biotech S.L. Nowa terapia amyloidozy związanej z transtyretyną
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
WO2014141261A1 (en) * 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
CN105873631B (zh) * 2013-11-05 2021-06-18 辛纳吉勒公司 经由口腔进行连续药物递送的装置和方法
EP3188725B1 (en) * 2014-09-04 2020-10-28 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Similar Documents

Publication Publication Date Title
JP2015096530A5 (OSRAM)
WO2014160441A8 (en) Neuroactive steroids, compositions, and uses thereof
JP2015081257A5 (OSRAM)
JP2015525757A5 (OSRAM)
JP2019508789A5 (OSRAM)
WO2015195483A3 (en) Graphene and graphene-related materials for manipulation of cell membrane potential
WO2016168784A3 (en) Rna nanoparticles and method of use thereof
JP2014237817A5 (OSRAM)
JP2013224923A5 (OSRAM)
JP2014530840A5 (OSRAM)
WO2015023681A3 (en) Swallowing assessment and improvement systems and methods
WO2016059019A3 (en) Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use
JP2016135110A5 (OSRAM)
WO2016142708A3 (en) Pharmaceutical composition
AU2014233420A8 (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
JP2019094312A5 (OSRAM)
JP2014500802A5 (OSRAM)
JP2019523305A5 (OSRAM)
WO2015095659A3 (en) Indirubin solid dispersion composition
JP2016507627A5 (OSRAM)
FR3011547B1 (fr) Materiau composite solide alveolaire comportant des nanoparticules metalliques, procede de preparation et utilisations pour le stockage reversible de l'hydrogene
WO2013024494A3 (en) Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
WO2016015055A8 (en) Colon cleansing compositions